U.S. markets closed
  • S&P Futures

    3,664.00
    -3.25 (-0.09%)
     
  • Dow Futures

    29,831.00
    -37.00 (-0.12%)
     
  • Nasdaq Futures

    12,461.75
    +7.50 (+0.06%)
     
  • Russell 2000 Futures

    1,836.90
    -0.60 (-0.03%)
     
  • Crude Oil

    45.12
    -0.16 (-0.35%)
     
  • Gold

    1,829.80
    -0.40 (-0.02%)
     
  • Silver

    24.01
    -0.07 (-0.29%)
     
  • EUR/USD

    1.2117
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    0.9480
    +0.0140 (+1.50%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3366
    -0.0010 (-0.07%)
     
  • USD/JPY

    104.4660
    +0.0420 (+0.04%)
     
  • BTC-USD

    18,999.87
    -236.98 (-1.23%)
     
  • CMC Crypto 200

    372.68
    +7.76 (+2.13%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,746.94
    -54.04 (-0.20%)
     

Pawar Law Group Reminds Nano-X Imaging Ltd. Investors of IMPORTANT NOV. 16 DEADLINE in Securities Class Action– NNOX

Pawar Law Group
·2 min read

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nano-X Imaging Ltd. (NASDAQ: NNOX) from August 21, 2020 through September 15, 2020 inclusive (the “Class Period”). The lawsuit seeks to recover damages for Nano-X Imaging Ltd. investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nanox System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nanox System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
-------------------------------

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com